{"id":"reduced-dose-of-doac","safety":{"commonSideEffects":[{"rate":null,"effect":"Major bleeding"},{"rate":null,"effect":"Minor bleeding"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Intracranial hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL3037806","moleculeType":"Small molecule","molecularWeight":"326.40"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"DOACs work by directly inhibiting Factor Xa or thrombin (Factor IIa) in the coagulation cascade, preventing the formation of blood clots. Dose reduction strategies aim to maintain therapeutic efficacy in specific patient populations (such as those with renal impairment, low body weight, or advanced age) while reducing the incidence of major bleeding complications. This phase 3 trial likely evaluates the safety and efficacy of reduced dosing regimens compared to standard dosing.","oneSentence":"A reduced dose of a direct oral anticoagulant (DOAC) inhibits specific coagulation factors to prevent thrombus formation while minimizing bleeding risk through dose optimization.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:41.524Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism prevention and treatment"}]},"trialDetails":[{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT04642430","phase":"PHASE4","title":"COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-07-06","conditions":"Atrial Fibrillation","enrollment":3018},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT03285438","phase":"PHASE3","title":"REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2017-11-02","conditions":"Venous Thromboembolism","enrollment":2774},{"nctId":"NCT04436978","phase":"PHASE4","title":"What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?","status":"RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2023-01-11","conditions":"Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation","enrollment":2000},{"nctId":"NCT04730037","phase":"PHASE3","title":"Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2021-03-23","conditions":"CTEPH","enrollment":74},{"nctId":"NCT02666742","phase":"PHASE4","title":"DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation","status":"COMPLETED","sponsor":"Kansas City Heart Rhythm Institute","startDate":"2017-02-16","conditions":"Ventricular Tachycardia, Premature Ventricular Contraction, Stroke","enrollment":246},{"nctId":"NCT04191928","phase":"PHASE1","title":"Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2020-03-03","conditions":"Pancreas Cancer, DVT, Pulmonary Embolism","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":191,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Reduced dose of DOAC","genericName":"Reduced dose of DOAC","companyName":"University Hospital, Brest","companyId":"university-hospital-brest","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A reduced dose of a direct oral anticoagulant (DOAC) inhibits specific coagulation factors to prevent thrombus formation while minimizing bleeding risk through dose optimization. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}